|Products/services:||Drug discovery and development|
|Location(s):||Dresden, Frankfurt am Main, Boston|
|Date of foundation:||2018|
|Number of employees:||130|
|About the company/organisation:||Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. We believe that a vast range of conditions arise from the dysfunction or aberrant composition of condensates (condensatopathy) — including cancer, neurodegeneration, cardiopulmonary disorders, and metabolic disease. We are employing our integrated wet lab/machine learning platform to identify a suite of condensate-modulators (c-mods) with the potential to alter the course of these diseases. Our scientists work in Boston, Dresden, and Frankfurt to translate condensate biology into treatments for the toughest diseases.
Learn more at dewpointx.com, and follow us on Twitter and LinkedIn.
Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.
|Recruitments per year:||30|
|Area of expertise:||
|Desired additional skills (soft skills):||fluent English|
|Career opportunities:||All levels|
Dewpoint Therapeutics GmbH